APIXORA

APIXORA Strategic Investment

APIXORA Strategic Investment & Growth Roadmap

Building a New Standard for the Global Pharmaceutical B2B Market

APIXORA is a global pharmaceutical B2B platform that directly connects Korean pharmaceutical companies with global API manufacturers and authorized suppliers.

Beyond simple product search, APIXORA is designed to integrate the entire API transaction process into a single platform, including RFQs, competitive bidding, supplier matching, contracts, CDAs, samples, KDMF·MFDS regulatory support, PO·PI management, and project management.

APIXORA is building a digital transaction infrastructure connecting the Korean pharmaceutical market with the global API supply chain, with the long-term goal of evolving into a global pharmaceutical supply chain platform.

APIXORA aims to provide strategic partners and investors with phased equity participation opportunities to share in the platform's long-term growth potential and future enterprise value.

Why Invest in APIXORA

The Industry Is at an Inflection Point

The global pharmaceutical industry is undergoing several major transformations simultaneously: the restructuring of global supply chains, increasing regulatory complexity, the growing adoption of AI-driven decision-making, and the continued expansion of the global API market.

Since COVID-19, governments and pharmaceutical companies have placed greater emphasis on supply chain resilience and supplier diversification, while the regulatory and collaboration environment surrounding global pharmaceutical supply chains—including DMF, GMP, audits, and regulatory collaboration—has become increasingly complex.

At the same time, AI and data are transforming corporate procurement and supply chain decision-making, making them faster, more sophisticated, and increasingly data-driven.

Yet supplier discovery, RFQs, price negotiations, regulatory reviews, contracts, and project management in the global API market remain fragmented across email, messaging platforms, offline exhibitions, trading companies, and individual business networks.

APIXORA aims to connect these fragmented API transactions and supply chains through a single digital platform and build a new digital operating infrastructure integrating transactions, regulatory processes, project management, data, and AI.

API Is the Starting Point

APIXORA begins with Active Pharmaceutical Ingredients (APIs), but its long-term vision extends beyond API transactions.

Starting with APIs, APIXORA aims to progressively expand its platform ecosystem into Pharmaceutical Intermediates, Excipients, Veterinary APIs, CDMO, Regulatory Collaboration, Enterprise SaaS, and AI-powered Procurement, ultimately evolving into a digital infrastructure connecting the global pharmaceutical supply chain.

Network × Data × AI

As more buyers and suppliers join the platform, more RFQs and transaction projects are generated. As transactions and projects increase, APIXORA accumulates increasingly valuable supplier, product, transaction, and regulatory data.

This accumulated data can enhance AI-powered supplier recommendations, supply chain analysis, and procurement decision-making. More accurate and efficient matching can, in turn, generate more transactions and recurring business.

  1. More Buyers & Suppliers
  2. More RFQs & Transactions
  3. Data Accumulation
  4. Enhanced AI Analysis & Matching
  5. More Transactions & Recurring Business
  6. Increased Platform Enterprise Value

Through this virtuous cycle of network effects and data accumulation, APIXORA aims to continuously strengthen its platform competitiveness and increase enterprise value.

Investment Strategy

APIXORA's investment strategy goes beyond capital raising.

Our priority is to establish strategic investments and business partnerships that will jointly expand the global API supply chain, strengthen access to the Korean pharmaceutical market, and accelerate the growth of our digital platform ecosystem.

Potential Strategic Partners

  • Global pharmaceutical companies
  • Global API manufacturers and authorized suppliers
  • Strategic Investors (SI)
  • Venture Capital (VC)
  • Corporate Venture Capital (CVC)
  • Institutional investors
  • Global B2B platform and technology companies
  • Strategic partners in logistics, AI, and data solutions

No investment or partnership with any specific company has been finalized. APIXORA continuously evaluates potential partners based on long-term strategic synergy and sustainable growth opportunities.

Long-term Investment Roadmap

YearInvestment PhaseEquity Under ConsiderationTarget Enterprise Value (Illustrative)
2026Strategic Partner RoundUp to 10%Approx. KRW 20 Billion
2027Growth RoundAdditional Up to 20%Approx. KRW 40 Billion
2028Global Expansion RoundAdditional Up to 10%Approx. KRW 80 Billion
2029Global Business ExpansionSubject to Business NeedsTo Be Determined Based on Business Performance
2030IPO PreparationSubject to IPO StructureSubject to Market Valuation
Phase 1 · 2026

Strategic Partner Round

APIXORA will establish the foundation of its two-sided marketplace by simultaneously expanding its Korean pharmaceutical buyer network and its global API manufacturer and supplier ecosystem.

Key Objectives

  • Expand Korean pharmaceutical buyer network
  • Expand global API manufacturers and authorized suppliers
  • Activate RFQs and competitive bidding
  • Launch commercial transactions through the platform
  • Validate business model and revenue generation
  • Strengthen KDMF and MFDS regulatory support services
  • Digitize the entire API sourcing process

Investment Focus

  • Strategic partner investments
  • Consider secondary share transactions of up to 10%
  • Illustrative Target Enterprise Value: Approx. KRW 20 Billion

2026 Vision — Establish the market foundation of a digital platform connecting Korean pharmaceutical buyers with global API suppliers.

Phase 2 · 2027

Growth Round

Following successful market validation, APIXORA will significantly expand its user base, transaction volume, and commercial activities.

Key Objectives

  • Expand membership among major Korean pharmaceutical companies
  • Grow the global API manufacturer network
  • Increase recurring commercial projects
  • Develop AI-powered supplier recommendation systems
  • Strengthen platform competitiveness through transaction data
  • Expand KDMF registration projects
  • Establish sustainable revenue models

Investment Focus

  • Growth investment round
  • Consider additional secondary share transactions of up to 20%
  • Illustrative Target Enterprise Value: Approx. KRW 40 Billion

2027 Vision — Become Korea's leading digital platform for pharmaceutical API sourcing.

Phase 3 · 2028–2029

Global Expansion

Expand the proven Korean business model into international markets and establish a truly global API trading ecosystem.

Key Objectives

  • Enter Japan, Southeast Asia, the Middle East, and European markets
  • Expand global API manufacturers and authorized agents
  • Build country-specific regulatory databases
  • Enhance AI-driven supply chain intelligence
  • Activate global RFQs and multi-country competitive bidding
  • Secure overseas strategic partners
  • Establish a global API trading ecosystem

Investment Focus

  • Global expansion investment
  • Consider additional secondary share transactions of up to 10%
  • Illustrative Target Enterprise Value: Approx. KRW 80 Billion

2028–2029 Vision — Transform APIXORA into a leading global API trading platform.

Phase 4 · 2030

IPO Preparation

Based on stable commercial performance and a global supply network, APIXORA aims to begin formal preparations for an Initial Public Offering (IPO).

Key Objectives

  • Establish sustainable revenue streams
  • Expand global buyers and suppliers
  • Strengthen corporate governance
  • Build robust internal control and financial reporting systems
  • Enhance cybersecurity and data governance
  • Prepare for IPO requirements
  • Strengthen the APIXORA global brand

2030 Vision — Become one of the world's leading digital platforms for the pharmaceutical API industry.

Value Created by APIXORA

For Korean Pharmaceutical Companies

  • Access to competitive global API suppliers
  • Procurement cost reduction
  • Supply chain diversification
  • Transparent supplier comparison and competitive bidding
  • KDMF and MFDS regulatory support
  • End-to-end procurement management

For Global API Manufacturers & Suppliers

  • Direct access to the Korean pharmaceutical market
  • New buyer acquisition opportunities
  • Real-time RFQ opportunities
  • Korean regulatory and KDMF support
  • Integrated sales, contracting, and post-sales management

For Investors & Strategic Partners

  • High barriers to entry through pharmaceutical industry expertise
  • Two-sided marketplace connecting Korean buyers and global suppliers
  • Recurring B2B transaction-based business model
  • AI-powered API trading platform
  • Increasing enterprise value through accumulated transaction data
  • Highly scalable global expansion model

Investment & Partnership Opportunities

APIXORA is open to the following forms of strategic collaboration:

  • Strategic equity investment
  • Investment linked to strategic business partnerships
  • Joint domestic and international market expansion
  • Joint development of global supply chains
  • Strategic collaboration in AI, data, and logistics
  • Long-term growth partnerships

Strategic Equity Participation

APIXORA aims to provide strategic partners with phased equity participation opportunities based on the platform's growth stage and business performance.

The company aims to continuously increase enterprise value through the achievement of key milestones at each stage, including the establishment of its initial market foundation, expansion of commercial transactions, enhancement of data and AI capabilities, and entry into global markets.

Beyond purely financial investment, APIXORA welcomes strategic investors and partners who share our vision of driving the digital transformation of the global pharmaceutical supply chain and creating long-term enterprise value together.

Investment Inquiries

APIXORA welcomes inquiries from strategic investors, institutional investors, and business partners who share our vision for the future value and long-term growth potential of the global pharmaceutical supply chain platform that APIXORA is building.

Investment & Strategic Partnership — contact@apixora.com

Disclaimer

This roadmap is intended to present APIXORA's current business strategy and long-term growth vision.

The enterprise values presented herein are illustrative targets based on the successful achievement of each development phase and should not be interpreted as fixed valuations or investment terms. Actual investment terms, company valuation, ownership structure, and IPO plans will be determined based on business performance, financial results, market conditions, strategic considerations, and discussions with prospective investors.